Indian pharmaceutical companies are not rushing to relocate manufacturing to the United States despite former President Donald Trump's renewed threat of tariffs up to 200 per cent on imported generic drugs. Instead, they are leveraging existing US plants, contract manufacturers, and making selective investments in complex products while maintaining India as their primary production hub.
Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after analysts remained cautious on the company's Q3 performance and differed on its growth outlook. DRL's Q3 performance was viewed as subdued by some analysts when they adjusted it for one-time grants and incomes that the company received during the quarter.
